RxDoctor Payments Data

Thomas Bossi, DO

Family Medicine · Davison, MINPI 1346342235

Payments from drug & device makers

$8,002in general payments, 2019–2025

Across 459 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$1K
  • Novo Nordisk$549
  • Lilly USA, LLC$436
  • Amgen$434
  • Amarin Pharma, Inc.$370
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$7,92299%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,002 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$135,070
Medicare patients
340
Services billed
5,739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban114$129,551
JanuviaSitagliptin Phosphate62$65,228
XareltoRivaroxaban24$35,581
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$34,901
TrulicityDulaglutide14$33,763
ProliaDenosumab15$25,814
RybelsusSemaglutide16$21,609
MounjaroTirzepatide20$21,228
OzempicSemaglutide21$20,745
JardianceEmpagliflozin24$20,582
EntrestoSacubitril/Valsartan14$18,868
Levemir FlexpenInsulin Detemir35$11,263
Breo ElliptaFluticasone/Vilanterol11$8,385
PremarinEstrogens, Conjugated16$7,541
FenofibrateFenofibrate Nanocrystallized184$5,566

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Prempro$293$139,927142 claims
MerckJanuvia$66$65,22862 claims
Lilly USA, LLCTrulicity, Mounjaro$436$54,99034 claims
GSKTrelegy Ellipta, Breo Ellipta$1,188$43,28657 claims
Novo NordiskRybelsus, Ozempic$549$42,35437 claims
Johnson & JohnsonXarelto$233$35,58124 claims
AmgenProlia$434$25,81415 claims
Boehringer IngelheimJardiance$117$20,58224 claims
NovartisEntresto$161$18,86814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Davison

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →